Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline Review, H2 2016’, provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Polyarticular Juvenile Idiopathic Arthritis (PJIA)

The report reviews pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Polyarticular Juvenile Idiopathic Arthritis (PJIA) therapeutics and enlists all their major and minor projects

The report assesses Polyarticular Juvenile Idiopathic Arthritis (PJIA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biocon Ltd

Coherus BioSciences Inc

Livzon Pharmaceutical Group Inc

Marathon Pharmaceuticals LLC

Momenta Pharmaceuticals Inc

Mycenax Biotech Inc

NeuClone Pty Ltd

Oncobiologics Inc

Oncodesign SA

Panacea Biotec Ltd

Regeneron Pharmaceuticals Inc

Sandoz International GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Polyarticular Juvenile Idiopathic Arthritis (PJIA) Overview 7

Therapeutics Development 8

Pipeline Products for Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview 8

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics under Development by Companies 9

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Unknown Stage Products 13

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Products under Development by Companies 14

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development 15

Biocon Ltd 15

Coherus BioSciences Inc 16

Livzon Pharmaceutical Group Inc 17

Marathon Pharmaceuticals LLC 18

Momenta Pharmaceuticals Inc 19

Mycenax Biotech Inc 20

NeuClone Pty Ltd 21

Oncobiologics Inc 22

Oncodesign SA 23

Panacea Biotec Ltd 24

Regeneron Pharmaceuticals Inc 25

Sandoz International GmbH 26

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

abatacept biosimilar - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

adalimumab biosimilar - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

adalimumab biosimilar - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

adalimumab biosimilar - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

adalimumab biosimilar - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

adalimumab biosimilar - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

adalimumab biosimilar - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

deflazacort - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

etanercept biosimilar - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

etanercept biosimilar - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

etanercept biosimilar - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

etanercept biosimilar - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

etanercept biosimilar - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

methotrexate - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

sarilumab - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

tocilizumab biosimilar - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

tocilizumab biosimilar - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

tocilizumab biosimilar - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects 65

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Product Development Milestones 66

Featured News & Press Releases 66

Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept) 66

Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel 66

Jul 13, 2016: Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases 67

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

List of Tables

Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Comparative Analysis by Unknown Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Biocon Ltd, H2 2016 15

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Coherus BioSciences Inc, H2 2016 16

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Livzon Pharmaceutical Group Inc, H2 2016 17

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Marathon Pharmaceuticals LLC, H2 2016 18

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Momenta Pharmaceuticals Inc, H2 2016 19

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Mycenax Biotech Inc, H2 2016 20

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by NeuClone Pty Ltd, H2 2016 21

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Oncobiologics Inc, H2 2016 22

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Oncodesign SA, H2 2016 23

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Panacea Biotec Ltd, H2 2016 24

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 25

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Pipeline by Sandoz International GmbH, H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Dormant Projects, H2 2016 65

List of Figures

List of Figures

Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Targets, H2 2016 28

Number of Products by Stage and Targets, H2 2016 28

Number of Products by Mechanism of Actions, H2 2016 30

Number of Products by Stage and Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports